The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Molecular Dissection Of Cytokine-mediated Regulation Of Human B-cell Differentiation.
Funder
National Health and Medical Research Council
Funding Amount
$119,314.00
Summary
Interleukin 21 is a molecule which activates B cells. Defects in this pathway cause immunodeficiency where individuals cannot make antibodies, while constant activation has been reported in mouse models of autoimmunity. Examining these pathways will shed light on the causes of human immune disease, and may reveal molecules that could be targeted for the treatment of immunodeficiency and autoimmunity. Amplification of normal immune responses could lead to the development of improved vaccines.
The Use Of Positron Emission Tomography (PET), Novel Immune And Microbiological Biomarkers To Improve The Diagnosis And Prognostication Of Giant Cell Arteritis
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
Giant cell arteritis (GCA) is an inflammatory condition of blood vessels. Diagnosing the condition and predicting which patients will develop complications is challenging. Undiagnosed, a significant proportion of patients experience sudden onset, permanent blindness. Our study aims to improve the diagnosis and risk assessment of patients with suspected GCA by following a group of 65 patients for two years with serial scans, blood tests and clinical reviews.
A Novel Approach To Cytokine Blockade For The Treatment Of Systemic Lupus Erythematosus
Funder
National Health and Medical Research Council
Funding Amount
$137,700.00
Summary
Lupus is a disease of the immune system which can cause inflammation and damage to many organs and even death, often affecting young people in their prime of life. Current treatments are limited and often have undesirable side effects. Certain cells and molecules are thought to be responsible for causing lupus. This project will examine the effect of blocking one of these molecules as a means of treating lupus. It will also use gene and protein analysis of samples from lupus patients to see if r ....Lupus is a disease of the immune system which can cause inflammation and damage to many organs and even death, often affecting young people in their prime of life. Current treatments are limited and often have undesirable side effects. Certain cells and molecules are thought to be responsible for causing lupus. This project will examine the effect of blocking one of these molecules as a means of treating lupus. It will also use gene and protein analysis of samples from lupus patients to see if response to treatments can be predicted.Read moreRead less
Investigation Of The Use Of Innate And CD1-mediated Immune Responses As Biomarkers In Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$144,836.00
Summary
Tuberculosis and other non-tuberculosis mycobacterial infections are major health problems worldwide. There are multiple challenges facing treatment and identification of active versus latent TB infections currently. This project aims to identify and characterise several aspects of the immune system which may be responsible for people developing active infections, including ones which may enable development of diagnostic tests and to monitor treatment. Such a biomarker may also help hasten new d ....Tuberculosis and other non-tuberculosis mycobacterial infections are major health problems worldwide. There are multiple challenges facing treatment and identification of active versus latent TB infections currently. This project aims to identify and characterise several aspects of the immune system which may be responsible for people developing active infections, including ones which may enable development of diagnostic tests and to monitor treatment. Such a biomarker may also help hasten new drug therapies for tuberculosis.Read moreRead less
Double Blind, Randomised Controlled Trial Assessing The Efficacy Of Endothelin-1 Receptor Antagonism In Preventing Peri-procedural Myonecrosis In Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Funder
National Health and Medical Research Council
Funding Amount
$124,608.00
Summary
While the focus in the treatment of coronary artery disease has primarily been on the large vessels in the heart, vessels of small calibre may also play a significant role in patients with angina, heart attack, and muscle injury related to a stenting procedure.This project aims elucidate the possible mechanisms which cause dysfunction in these small vessels. I also hope to find a treatment strategy which may benefit patients with small vessel problems and thus improve their overall outcome.
Suppression Of Immunity By The Malaria Parasite Antigen Plasmodium Falciparum Erythrocyte Membrane Protein-1 (PfEMP-1)
Funder
National Health and Medical Research Council
Funding Amount
$96,698.00
Summary
The malaria parasite P. falciparum infects red blood cells and makes the cells put on their surface a protein called PfEMP-1. The parasite can effectively “hide” by constantly changing this protein and making it unrecognizable by the immune system. PfEMP-1 can also suppress the immune system so that it can’t respond adequately to infection. Therefore, understanding PfEMP-1 function is important. I will investigate how PfEMP-1 can do this by looking at its cross talk with the immune system.
Establishing The Clinical Spectrum And Pathogenicity Of Antibodies Against Dopamine Receptors In Autoimmune Movement And Psychiatric Disorders
Funder
National Health and Medical Research Council
Funding Amount
$172,126.00
Summary
Dopamine plays a pivotal role in neurotransmission and the control of movement and behaviour. This project aims to define the clinical spectrum and pathogenicity of anti-dopamine receptor antibody mediated diseases. The identification of these antibodies in atypical presentations of common movement disorders would have widespread diagnostic and therapeutic implications, and suggests that selected patients might be amenable to targeted immunomodulatory therapy, thus improving their outcome.
The Role Of Redox Regulation In Controlling The Oncogenic Function Of Eph Receptors
Funder
National Health and Medical Research Council
Funding Amount
$71,766.00
Summary
Reactive oxygen species (ROS) produced in cancers activate cell surface receptor signalling pathways that drive cancer progression. I will study links between ROS and receptor signalling in cancer cells, and inhibit signalling with ROS scavengers delivered in nanoparticles, targeted to receptor complexes with specific antibodies. These will include antibodies we raised against ADAM10, a protease associated with multiple receptor signalling pathways, to simultaneously inhibit these pathways.
Neurobiology Of Relaxin-3/RXFP3 Systems: Anatomical And Functional Studies In Transgenic Mice
Funder
National Health and Medical Research Council
Funding Amount
$94,242.00
Summary
Mental illness is an economic and health burden worldwide, with huge costs in medical spending, lost productivity, poor quality of life for sufferers and mortality. Relaxin-3 is a peptide that acts widely within neural circuits to modulate brain activity that is altered in conditions such as anxiety and mood/sleep disorders. Our research assessing the effect of genetic removal of relaxin-3 signaling on behaviour will add to our knowledge of brain function and improve mental health outcomes.